Pacira Pharmaceuticals buy JPMorgan Chase & Co.
Start price
07.03.24
/
50%
€28.20
Target price
07.03.25
€41.38
Performance (%)
-30.14%
Price
05.07.24
€19.60
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ for Pacira Pharmaceuticals is performing very badly with a performance of -30.14%. This prediction currently runs until 07.03.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -23.438% | -23.438% |
iShares Core DAX® | 1.395% | -0.272% |
iShares Nasdaq 100 | 2.287% | 6.912% |
iShares Nikkei 225® | 1.617% | 3.038% |
iShares S&P 500 | 0.659% | 3.687% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat